
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Journal
- Events
- Suppliers
Suppliers
- Home
- Industry news
Industry news
- Category news
- Reports
- Key trends
- Multimedia
Multimedia
- Events
- Suppliers
Suppliers
11 Jul 2014 --- As a result of the successful conclusion of the regulatory process and customary closing conditions, Nestlé has completed its acquisition of Valeant Pharmaceuticals International’s commercialisation rights to several key injectable aesthetic dermatology products in the US and Canada, as announced on 28 May 2014. These rights will be integrated into Nestlé Skin Health and commercialised by Galderma.
Based in Lausanne, Nestlé Skin Health is a global leader focused on enhancing the quality of life by delivering science-based solutions for the health of skin, hair and nails. Galderma, with approximately 5,000 employees and a presence in 80 countries, is the pharmaceutical arm of Nestlé Skin Health.
Upcoming webinars

Bifidobacteria and Healthy Ageing: New Insights into Ageing and Immunity
Morinaga

The future of infant nutrition: From science to success
Valio

From tiny guts to big impact: the powerful potential of probiotics in children’s health
Novonesis











